52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
- 1 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (8), 1700-1709
- https://doi.org/10.1097/mib.0b013e318281f2b7
Abstract
The results of an open-label follow-up until week 52 of patients with moderately to severely active ulcerative colitis who participated in a double-blind placebo-controlled adalimumab induction trial (ULTRA 1, NCT00385736) are reported. The study included adult anti–tumor necrosis factor–naive patients who completed double-blind adalimumab induction under an amended protocol (intent-to-treat [ITT]-A3 population) or any version of the protocol (ITT-E). Patients randomized to placebo received adalimumab beginning at week 8; patients randomized to adalimumab continued every other week dosing. Weekly dosing was allowed beginning at week 14 (original protocol) or week 12 (amended protocol). Clinical remission (Mayo score ≤2, no subscore >1), clinical response (decrease in Mayo score ≥3 points and ≥30% from baseline, plus decrease in rectal bleeding subscore ≥1 or absolute rectal bleeding subscore ≤1), mucosal healing (endoscopy subscore ≤1), escalation to weekly dosing, and reduction in corticosteroid use were assessed at week 52 in the pooled ITT-A3 and pooled ITT-E populations, using modified nonresponder imputation. Rates of clinical remission, clinical response, and mucosal healing at week 52 for the ITT-A3 population (N = 390) were 29.5%, 53.6%, and 46.7%, respectively; 38.8% of week 8 responders achieved clinical remission at week 52. Of patients using baseline corticosteroids (N = 234), 56.0% were corticosteroid-free at week 52 (26.1% in clinical remission). Results of the ITT-E population were similar. No new safety issues were identified. In this open-label study, adalimumab was effective for maintaining clinical remission in anti–tumor necrosis factor–naive patients with moderately to severely active ulcerative colitis who did not adequately respond to conventional therapy.Keywords
This publication has 8 references indexed in Scilit:
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel diseaseJournal of Crohn's and Colitis, 2011
- Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative ColitisClinical Gastroenterology and Hepatology, 2011
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeThe American Journal of Gastroenterology, 2010
- Importance of mucosal healing in ulcerative colitisInflammatory Bowel Diseases, 2010
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scandinavian Journal of Gastroenterology, 2009
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007